An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.
about
Interventions for guttate psoriasisSystemic pharmacological treatments for chronic plaque psoriasisThe role of the CD58 locus in multiple sclerosisTailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapiesInducing and Administering Tregs to Treat Human DiseaseFc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeuticsOff-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapyPutting together the psoriasis puzzle: an update on developing targeted therapiesBiologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring.Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study.Biologics in dermatologic therapy - an update.Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgarisEfficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry.Psoriasis (chronic plaque)Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasisA practical approach to monitoring patients on biological agents for the treatment of psoriasisComparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab.An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic options.The long-term efficacy and safety of new biological therapies for psoriasisBiologics in the management of psoriasis.Update of the management of chronic psoriasis: new approaches and emerging treatment options.Dissecting the psoriasis transcriptome: inflammatory- and cytokine-driven gene expression in lesions from 163 patientsPsoriasis treatment: current and emerging directed therapies.Psoriasis and the new biologic agents: interrupting a T-AP danceBiological therapies in the systemic management of psoriasis: International Consensus Conference.Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies; U.S. experiences.Alefacept: a review of the literature and practical guidelines for management.Alefacept is well tolerated in patients with chronic plaque psoriasis.Psoriasis: emerging therapeutic strategies.Psoriatic arthritis treatment: biological response modifiersThe psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis.Efalizumab: continuous therapy for chronic psoriasis.Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks.Cutaneous adverse events of biological therapy for psoriasis: review of the literature.Alefacept: an expert review concerning the treatment of psoriasis.Alefacept for psoriasis and psoriatic arthritis.The vertebral artery: a review of anatomical, histopathological and functional factors influencing blood flow to the hindbrain.T cell targeted immunotherapy for autoimmune disease.Infliximab for inpatient psoriasis management--is there a role?Cost-effectiveness of moderate-to-severe psoriasis treatment.
P2860
Q24188296-EF49FD8C-ACB1-43B3-BAFE-6CF0B04803DAQ24188334-5D78824E-E694-46E5-90B7-45021DEF48F9Q24649291-15E39222-1C68-4447-862E-8D87868B988EQ26764867-6A0613EE-720F-4657-93A8-4CEB70196F3FQ26772723-E96F64F4-D9F1-4E69-B448-009BFF268C94Q26822421-6887C65B-BD15-4410-97E1-F9BEA9DD833CQ26827714-AA51D771-D3EB-4E10-A807-6A6CCDD93E25Q27026785-3740B252-00C2-46A2-8152-DFFA3910D78AQ30412650-58CD5E12-454F-4C77-BCF0-8B46E3E8CF98Q31034753-28A4DB42-C194-4310-8ACB-D9ECB7C6B7A5Q33607620-F3DED259-ED2C-4A37-8D21-EF380297A07FQ33757065-2C927042-1904-481A-AC87-84102890D4C7Q33896449-3D8FA6AD-ABA2-487F-A181-6D10FE25E87BQ34010557-9F300605-39B6-4B43-A68E-EE31FA734518Q34041797-5A75BD70-4A99-4D19-B429-6241A10EE6F3Q34156420-BCF1CF17-CE68-4578-9A83-910EFC31932BQ34502118-745A622C-F91D-4E35-AA56-97B131DD8F00Q34610829-ABF84072-11C2-4D39-9476-D77A160D49B7Q34613199-25F3BA5F-8A4D-44AC-A3C4-21231AAE1224Q34620257-9B148837-5173-4E0A-8CAA-65884B874136Q34620375-57006A0C-6349-46DE-B8ED-6CF085357F42Q34894016-6F4A6E2A-258A-46D8-BACE-FA74930454B3Q35579427-D2FBCBAC-5F63-4AE1-9B5E-F1A851114E84Q35813465-D33BA274-96A9-40F5-A0BD-30A151F21298Q35841615-9A40E175-EF99-4B62-93FB-6A922E326B26Q35843827-26624543-30E0-4BEE-8806-AD3E864A15A6Q35893152-3696EB25-AB72-40CB-AB16-EE34FF1E35F5Q36019379-AE6A4E8A-F2F6-49CD-8B83-A276A73EB2B5Q36028220-0CD50CEE-3AC0-473F-B459-E6FCA69A49C6Q36040084-98FE1E73-2850-4313-982A-FED50B35D495Q36077729-A5C44F89-D550-498D-9C20-FDDFB7F31280Q36099478-8BBE115D-09D7-4164-A3E6-97673DC0AC27Q36102406-FD0A9B17-8EB5-4B04-998B-54DC82A4752DQ36276703-0A2B849B-6290-4BC3-9CE4-CD616D2EF55EQ36283748-B5C06854-0BD3-412A-A735-2F9C71B6CBBCQ36292648-C722DE6F-DE30-43BF-9B68-C2CDADB43C4CQ36356951-5B0BD743-D96A-45D6-8083-7DCCF510420BQ36359571-FB9BE6E5-AF03-41C2-BD22-1A5824AD0F3EQ36374589-3AB3B8BE-7C0B-4E42-9349-61082D56ACAFQ36376401-685FAB9C-05BE-4DF8-B568-5335E121B4E6
P2860
An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
An international, randomized, ...... with chronic plaque psoriasis.
@en
An international, randomized, ...... with chronic plaque psoriasis.
@nl
type
label
An international, randomized, ...... with chronic plaque psoriasis.
@en
An international, randomized, ...... with chronic plaque psoriasis.
@nl
prefLabel
An international, randomized, ...... with chronic plaque psoriasis.
@en
An international, randomized, ...... with chronic plaque psoriasis.
@nl
P2093
P921
P1433
P1476
An international, randomized, ...... with chronic plaque psoriasis.
@en
P2093
Alefacept Clinical Study Group
Enno Christophers
Janet Roberts
Jean P Ortonne
Mark Lebwohl
Richard Langley
P304
P356
10.1001/ARCHDERM.139.6.719
P577
2003-06-01T00:00:00Z